25 XP   0   0   10

Tempest Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Tempest Therapeutics Inc together

PenkeI guess you are interested in Tempest Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Tempest Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Tempest Therapeutics Inc

I send you an email if I find something interesting about Tempest Therapeutics Inc.

Quick analysis of Tempest Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of Tempest Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$1.21
Expected worth in 1 year
$1.60
How sure are you?
23.1%

+ What do you gain per year?

Total Gains per Share
$0.39
Return On Investment
12.3%

For what price can you sell your share?

Current Price per Share
$3.17
Expected price per share
$2.7606 - $9.77
How sure are you?
50%

1. Valuation of Tempest Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$3.17

Intrinsic Value Per Share

$-16.70 - $-12.37

Total Value Per Share

$-15.50 - $-11.16

2. Growth of Tempest Therapeutics Inc (5 min.)




Is Tempest Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$26.7m$27.2m-$16.9m-162.7%

How much money is Tempest Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$7.4m-$9.3m$1.9m25.5%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Tempest Therapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#548 / 1016

Most Revenue
#803 / 1016

Most Profit
#501 / 1016

Most Efficient
#249 / 1016

What can you expect buying and holding a share of Tempest Therapeutics Inc? (5 min.)

Welcome investor! Tempest Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Tempest Therapeutics Inc.

What can you expect buying and holding a share of Tempest Therapeutics Inc?

First you should know what it really means to hold a share of Tempest Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Tempest Therapeutics Inc is $3.17. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Tempest Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Tempest Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.21. Based on the TTM, the Book Value Change Per Share is $0.10 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.20 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Tempest Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.34-10.6%-0.33-10.5%-0.39-12.1%-0.34-10.8%-0.50-15.6%
Usd Book Value Change Per Share1.2639.7%0.103.1%-0.20-6.4%-0.04-1.3%-0.02-0.5%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share1.2639.7%0.103.1%-0.20-6.4%-0.04-1.3%-0.02-0.5%
Usd Price Per Share4.40-2.07-2.11-5.00-7.51-
Price to Earnings Ratio-3.26--1.53--1.36--3.71--3.66-
Price-to-Total Gains Ratio3.49--2.38--2.55--6.81--9.79-
Price to Book Ratio3.65-2.07-1.69-2.52-2.49-
Price-to-Total Gains Ratio3.49--2.38--2.55--6.81--9.79-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.17
Number of shares315
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.10-0.04
Usd Total Gains Per Share0.10-0.04
Gains per Quarter (315 shares)30.72-12.88
Gains per Year (315 shares)122.88-51.51
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
101231130-52-62
202462360-103-114
303693590-155-166
404924820-206-218
506146050-258-270
607377280-309-322
708608510-361-374
809839740-412-426
90110610970-464-478
100122912200-515-530

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.039.00.00.0%0.046.00.00.0%
Book Value Change Per Share1.03.00.025.0%4.08.00.033.3%6.014.00.030.0%9.030.00.023.1%12.034.00.026.1%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.039.00.0%0.00.046.00.0%
Total Gains per Share1.03.00.025.0%4.08.00.033.3%6.014.00.030.0%9.030.00.023.1%12.034.00.026.1%

Fundamentals of Tempest Therapeutics Inc

About Tempest Therapeutics Inc

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.

Fundamental data was last updated by Penke on 2024-04-12 20:19:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is just not able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Tempest Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Tempest Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Tempest Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Tempest Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-9.1%+9.1%
5Y-9.1%10Y-9,381.0%+9,371.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--197.2%+197.2%
TTM--210.4%+210.4%
YOY--279.3%+279.3%
5Y-9.1%-436.8%+427.7%
10Y-9,381.0%-599.3%-8,781.7%
1.1.2. Return on Assets

Shows how efficient Tempest Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Tempest Therapeutics Inc to the Biotechnology industry mean.
  • -14.5% Return on Assets means that Tempest Therapeutics Inc generated $-0.15 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Tempest Therapeutics Inc:

  • The MRQ is -14.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -22.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-14.5%TTM-22.2%+7.7%
TTM-22.2%YOY-15.7%-6.6%
TTM-22.2%5Y-15.8%-6.4%
5Y-15.8%10Y-15.0%-0.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-14.5%-13.6%-0.9%
TTM-22.2%-12.9%-9.3%
YOY-15.7%-11.9%-3.8%
5Y-15.8%-14.2%-1.6%
10Y-15.0%-16.2%+1.2%
1.1.3. Return on Equity

Shows how efficient Tempest Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Tempest Therapeutics Inc to the Biotechnology industry mean.
  • -28.0% Return on Equity means Tempest Therapeutics Inc generated $-0.28 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Tempest Therapeutics Inc:

  • The MRQ is -28.0%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -63.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-28.0%TTM-63.1%+35.2%
TTM-63.1%YOY-36.7%-26.5%
TTM-63.1%5Y-30.0%-33.1%
5Y-30.0%10Y-23.0%-7.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-28.0%-17.0%-11.0%
TTM-63.1%-16.1%-47.0%
YOY-36.7%-15.4%-21.3%
5Y-30.0%-20.0%-10.0%
10Y-23.0%-21.1%-1.9%

1.2. Operating Efficiency of Tempest Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Tempest Therapeutics Inc is operating .

  • Measures how much profit Tempest Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Tempest Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Tempest Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-9.1%+9.1%
5Y-9.1%10Y-9,374.7%+9,365.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--286.1%+286.1%
TTM--224.4%+224.4%
YOY--288.4%+288.4%
5Y-9.1%-475.2%+466.1%
10Y-9,374.7%-624.7%-8,750.0%
1.2.2. Operating Ratio

Measures how efficient Tempest Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Tempest Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y0.178-0.178
5Y0.17810Y89.309-89.130
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.997-2.997
TTM-3.247-3.247
YOY-3.766-3.766
5Y0.1785.675-5.497
10Y89.3097.857+81.452

1.3. Liquidity of Tempest Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Tempest Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.29 means the company has $4.29 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Tempest Therapeutics Inc:

  • The MRQ is 4.289. The company is very able to pay all its short-term debts. +2
  • The TTM is 2.844. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ4.289TTM2.844+1.445
TTM2.844YOY3.273-0.429
TTM2.8445Y5.026-2.182
5Y5.02610Y8.430-3.403
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.2893.930+0.359
TTM2.8444.251-1.407
YOY3.2735.436-2.163
5Y5.0266.045-1.019
10Y8.4306.363+2.067
1.3.2. Quick Ratio

Measures if Tempest Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Tempest Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 4.17 means the company can pay off $4.17 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Tempest Therapeutics Inc:

  • The MRQ is 4.169. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.704. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.169TTM2.704+1.464
TTM2.704YOY3.163-0.459
TTM2.7045Y4.772-2.068
5Y4.77210Y11.431-6.659
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.1693.629+0.540
TTM2.7044.065-1.361
YOY3.1635.397-2.234
5Y4.7725.993-1.221
10Y11.4316.277+5.154

1.4. Solvency of Tempest Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Tempest Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Tempest Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.48 means that Tempest Therapeutics Inc assets are financed with 48.1% credit (debt) and the remaining percentage (100% - 48.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Tempest Therapeutics Inc:

  • The MRQ is 0.481. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.769. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.481TTM0.769-0.287
TTM0.769YOY0.564+0.205
TTM0.7695Y0.605+0.163
5Y0.60510Y0.357+0.249
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4810.332+0.149
TTM0.7690.334+0.435
YOY0.5640.268+0.296
5Y0.6050.366+0.239
10Y0.3570.390-0.033
1.4.2. Debt to Equity Ratio

Measures if Tempest Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Tempest Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 92.8% means that company has $0.93 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Tempest Therapeutics Inc:

  • The MRQ is 0.928. The company is very able to pay all its debts with equity. +2
  • The TTM is 2.116. The company is just not able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ0.928TTM2.116-1.189
TTM2.116YOY1.307+0.810
TTM2.1165Y0.891+1.226
5Y0.89110Y0.508+0.382
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9280.381+0.547
TTM2.1160.390+1.726
YOY1.3070.334+0.973
5Y0.8910.434+0.457
10Y0.5080.466+0.042

2. Market Valuation of Tempest Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Tempest Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Tempest Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -3.26 means the investor is paying $-3.26 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Tempest Therapeutics Inc:

  • The EOD is -2.349. Based on the earnings, the company is expensive. -2
  • The MRQ is -3.260. Based on the earnings, the company is expensive. -2
  • The TTM is -1.534. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.349MRQ-3.260+0.911
MRQ-3.260TTM-1.534-1.726
TTM-1.534YOY-1.358-0.177
TTM-1.5345Y-3.711+2.177
5Y-3.71110Y-3.661-0.050
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.349-2.315-0.034
MRQ-3.260-2.560-0.700
TTM-1.534-2.664+1.130
YOY-1.358-4.122+2.764
5Y-3.711-6.258+2.547
10Y-3.661-6.108+2.447
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Tempest Therapeutics Inc:

  • The EOD is -2.845. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.949. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.708. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.845MRQ-3.949+1.104
MRQ-3.949TTM-1.708-2.240
TTM-1.708YOY-1.506-0.202
TTM-1.7085Y50.161-51.869
5Y50.16110Y23.317+26.844
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.845-3.067+0.222
MRQ-3.949-3.251-0.698
TTM-1.708-3.545+1.837
YOY-1.506-5.595+4.089
5Y50.161-8.315+58.476
10Y23.317-8.708+32.025
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Tempest Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 3.65 means the investor is paying $3.65 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Tempest Therapeutics Inc:

  • The EOD is 2.628. Based on the equity, the company is underpriced. +1
  • The MRQ is 3.648. Based on the equity, the company is fair priced.
  • The TTM is 2.071. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.628MRQ3.648-1.020
MRQ3.648TTM2.071+1.577
TTM2.071YOY1.693+0.378
TTM2.0715Y2.517-0.446
5Y2.51710Y2.491+0.026
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.6281.905+0.723
MRQ3.6482.111+1.537
TTM2.0712.095-0.024
YOY1.6932.836-1.143
5Y2.5173.443-0.926
10Y2.4913.794-1.303
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Tempest Therapeutics Inc.

3.1. Institutions holding Tempest Therapeutics Inc

Institutions are holding 29.328% of the shares of Tempest Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31BlackRock Inc2.64410.0001508928425855512.6274
2023-12-31FMR Inc2.24410.0002431932-215966-33.3333
2023-12-31Vanguard Group Inc0.91540176193-36120-17.0126
2023-12-31EAM Investors, LLC0.72890.10951403001403000
2023-12-31Fidelity International Ltd0.67320.000612957900
2023-12-31Geode Capital Management, LLC0.65420.00011259183484638.262
2023-12-31Ikarian Capital, LLC0.54860.04351056001056000
2023-12-31Susquehanna International Group, LLP0.54240.00011044061044060
2023-12-31Two Sigma Investments LLC0.52070.00110021586582635.0913
2023-12-31SIMPLEX TRADING, LLC0.35040.000267435674350
2023-09-30Citadel Advisors Llc0.2332044882448820
2023-12-31Bank of America Corp0.194603746237453416144.4444
2023-12-31TWO SIGMA SECURITIES, LLC0.18440.0015354831399165.0986
2023-12-31Northern Trust Corp0.174603359820045147.9008
2023-12-31Morgan Stanley - Brokerage Accounts0.1653031816314057641.1192
2023-12-31Advisor Group Holdings, Inc.0.13590.000226150261500
2023-12-31BOOTHBAY FUND MANAGEMENT, LLC0.12770.002824572245720
2023-12-31State Street Corporation0.1221023492234920
2023-12-31Group One Trading, LP0.10760.000220706207060
2023-12-31Virtu Financial LLC0.08770.005916885-8452-33.3583
Total 11.35510.16592185552+947182+43.3%

3.2. Funds holding Tempest Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.78410.000617400700
2023-12-31Pleiades Small Cap Equity A0.3390.036875236752360
2024-02-29Fidelity Extended Market Index0.31220.000769286-336-0.4826
2024-02-29LUX IM Global Medtech HX0.21630.08424801000
2024-03-31BlackRock Extended Equity Market K0.16290.00136147-490-1.3374
2024-02-29Fidelity Total Market Index0.10880.00012413500
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.09750.00152164617881474.927
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.07830.00151738514367476.0437
2024-02-29Fidelity Series Total Market Index0.07550.00011676200
2023-12-31NT Ext Equity Mkt Idx Fd - L0.05180.000911488241626.6314
2023-12-31Northern Trust Extended Eq Market Idx0.05180.000911488241626.6314
2024-02-29Fidelity Nasdaq Composite Index0.05140.00031141400
2024-02-29Spartan Total Market Index Pool E0.03370.0001748100
2024-03-31Extended Equity Market Fund M0.02010.0014459-71-1.5673
2024-02-29Spartan Extended Market Index Pool E0.01330.0004295133612.8489
2023-09-30BlackRock Extended Mkt Composite0.0110244100
2024-02-29Vanguard U.S. Eq Idx £ Acc0.00990218600
2023-12-31BNYM Mellon SL Market Completion UC10.00930.00212068205617133.3333
2023-12-31NT Ext Eq Mkt Indx Fd DC Lending Tier 50.00320.0015700579478.5124
2023-12-31NT Quality SCC US Fund - L0.00110.000424000
Total 2.43120.1341539530+114390+21.2%

3.3. Insider Transactions

Insiders are holding 3.159% of the shares of Tempest Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2022-04-29Thomas WoiwodeBUY21186442.36
2022-01-07Thomas W DubenskyBUY20004.78

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Tempest Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--1.2600.098+1192%-0.203+116%-0.041+103%-0.017+101%
Book Value Per Share--1.2060.468+158%1.230-2%1.369-12%2.831-57%
Current Ratio--4.2892.844+51%3.273+31%5.026-15%8.430-49%
Debt To Asset Ratio--0.4810.769-37%0.564-15%0.605-20%0.357+35%
Debt To Equity Ratio--0.9282.116-56%1.307-29%0.891+4%0.508+83%
Dividend Per Share----0%-0%-0%-0%
Eps---0.337-0.332-2%-0.385+14%-0.342+1%-0.495+47%
Free Cash Flow Per Share---0.279-0.310+11%-0.356+28%-0.328+18%-0.422+52%
Free Cash Flow To Equity Per Share--1.2690.091+1295%-0.228+118%0.160+694%0.095+1235%
Gross Profit Margin--1.0111.003+1%1.000+1%1.001+1%1.000+1%
Intrinsic Value_10Y_max---12.368--------
Intrinsic Value_10Y_min---16.704--------
Intrinsic Value_1Y_max---1.276--------
Intrinsic Value_1Y_min---1.698--------
Intrinsic Value_3Y_max---3.807--------
Intrinsic Value_3Y_min---5.110--------
Intrinsic Value_5Y_max---6.303--------
Intrinsic Value_5Y_min---8.507--------
Market Cap70348640.000-39%97644800.00046018995.600+112%46714160.000+109%111031791.120-12%166726162.995-41%
Net Profit Margin----0%-0%-0.0910%-93.8100%
Operating Margin----0%-0%-0.0910%-93.7470%
Operating Ratio----0%-0%0.178-100%89.309-100%
Pb Ratio2.628-39%3.6482.071+76%1.693+115%2.517+45%2.491+46%
Pe Ratio-2.349+28%-3.260-1.534-53%-1.358-58%-3.711+14%-3.661+12%
Price Per Share3.170-39%4.4002.074+112%2.105+109%5.003-12%7.513-41%
Price To Free Cash Flow Ratio-2.845+28%-3.949-1.708-57%-1.506-62%50.161-108%23.317-117%
Price To Total Gains Ratio2.516-39%3.493-2.384+168%-2.554+173%-6.810+295%-9.794+380%
Quick Ratio--4.1692.704+54%3.163+32%4.772-13%11.431-64%
Return On Assets---0.145-0.222+53%-0.157+8%-0.158+9%-0.150+3%
Return On Equity---0.280-0.631+126%-0.367+31%-0.300+7%-0.230-18%
Total Gains Per Share--1.2600.098+1192%-0.203+116%-0.041+103%-0.017+101%
Usd Book Value--26768000.00010388750.000+158%27293250.000-2%30378700.000-12%62827153.846-57%
Usd Book Value Change Per Share--1.2600.098+1192%-0.203+116%-0.041+103%-0.017+101%
Usd Book Value Per Share--1.2060.468+158%1.230-2%1.369-12%2.831-57%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.337-0.332-2%-0.385+14%-0.342+1%-0.495+47%
Usd Free Cash Flow---6182000.000-6881750.000+11%-7908500.000+28%-7270850.000+18%-9372846.154+52%
Usd Free Cash Flow Per Share---0.279-0.310+11%-0.356+28%-0.328+18%-0.422+52%
Usd Free Cash Flow To Equity Per Share--1.2690.091+1295%-0.228+118%0.160+694%0.095+1235%
Usd Market Cap70348640.000-39%97644800.00046018995.600+112%46714160.000+109%111031791.120-12%166726162.995-41%
Usd Price Per Share3.170-39%4.4002.074+112%2.105+109%5.003-12%7.513-41%
Usd Profit---7488000.000-7472500.0000%-9375500.000+25%-8165700.000+9%-11283102.564+51%
Usd Revenue----0%-0%177750.000-100%377358.974-100%
Usd Total Gains Per Share--1.2600.098+1192%-0.203+116%-0.041+103%-0.017+101%
 EOD+2 -6MRQTTM+25 -5YOY+25 -55Y+20 -1210Y+18 -14

4.2. Fundamental Score

Let's check the fundamental score of Tempest Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.349
Price to Book Ratio (EOD)Between0-12.628
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than14.169
Current Ratio (MRQ)Greater than14.289
Debt to Asset Ratio (MRQ)Less than10.481
Debt to Equity Ratio (MRQ)Less than10.928
Return on Equity (MRQ)Greater than0.15-0.280
Return on Assets (MRQ)Greater than0.05-0.145
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Tempest Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.251
Ma 20Greater thanMa 503.907
Ma 50Greater thanMa 1003.810
Ma 100Greater thanMa 2003.874
OpenGreater thanClose3.300
Total3/5 (60.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Net Interest Income  -718663-55-56-111-262-3731,096723
Total Other Income Expense Net -169114-55-56-111-83-19422026



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets51,603
Total Liabilities24,835
Total Stockholder Equity26,768
 As reported
Total Liabilities 24,835
Total Stockholder Equity+ 26,768
Total Assets = 51,603

Assets

Total Assets51,603
Total Current Assets40,363
Long-term Assets11,240
Total Current Assets
Cash And Cash Equivalents 39,230
Other Current Assets 1,133
Total Current Assets  (as reported)40,363
Total Current Assets  (calculated)40,363
+/-0
Long-term Assets
Property Plant Equipment 10,792
Long-term Assets Other 60
Long-term Assets  (as reported)11,240
Long-term Assets  (calculated)10,852
+/- 388

Liabilities & Shareholders' Equity

Total Current Liabilities9,411
Long-term Liabilities15,424
Total Stockholder Equity26,768
Total Current Liabilities
Short-term Debt 5,237
Short Long Term Debt 4,285
Accounts payable 845
Other Current Liabilities 3,329
Total Current Liabilities  (as reported)9,411
Total Current Liabilities  (calculated)13,696
+/- 4,285
Long-term Liabilities
Long term Debt 6,264
Capital Lease Obligations 10,112
Long-term Liabilities  (as reported)15,424
Long-term Liabilities  (calculated)16,376
+/- 952
Total Stockholder Equity
Common Stock22
Retained Earnings -165,263
Other Stockholders Equity 192,009
Total Stockholder Equity (as reported)26,768
Total Stockholder Equity (calculated)26,768
+/-0
Other
Capital Stock22
Cash and Short Term Investments 39,230
Common Stock Shares Outstanding 21,521
Liabilities and Stockholders Equity 51,603
Net Debt -18,569
Net Invested Capital 37,317
Net Working Capital 30,952
Property Plant and Equipment Gross 11,817
Short Long Term Debt Total 20,661



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-09-30
> Total Assets 
0
0
34,985
36,326
32,814
61,167
56,240
51,225
47,545
92,763
85,829
77,499
65,572
175,777
164,454
152,807
138,613
122,060
158,722
142,398
122,543
106,319
93,885
82,025
72,853
63,029
55,533
49,234
84,074
68,324
58,479
74,970
68,045
57,132
48,838
22,863
31,707
75,497
67,142
73,238
66,953
71,351
63,171
46,089
37,329
30,742
23,987
51,603
51,60323,98730,74237,32946,08963,17171,35166,95373,23867,14275,49731,70722,86348,83857,13268,04574,97058,47968,32484,07449,23455,53363,02972,85382,02593,885106,319122,543142,398158,722122,060138,613152,807164,454175,77765,57277,49985,82992,76347,54551,22556,24061,16732,81436,32634,98500
   > Total Current Assets 
0
0
34,276
35,579
31,965
60,184
55,262
50,407
45,077
90,070
82,615
73,614
61,878
171,334
159,162
145,322
129,861
112,739
150,111
133,454
116,444
101,150
89,094
77,607
68,781
59,133
54,175
48,986
83,422
64,512
53,652
71,132
64,624
54,072
46,089
19,825
29,394
70,494
62,557
68,963
62,710
68,307
60,257
32,950
24,673
18,535
12,291
40,363
40,36312,29118,53524,67332,95060,25768,30762,71068,96362,55770,49429,39419,82546,08954,07264,62471,13253,65264,51283,42248,98654,17559,13368,78177,60789,094101,150116,444133,454150,111112,739129,861145,322159,162171,33461,87873,61482,61590,07045,07750,40755,26260,18431,96535,57934,27600
       Cash And Cash Equivalents 
0
0
34,067
35,119
14,776
43,188
28,193
21,077
18,078
56,134
16,553
12,125
6,414
134,698
70,238
50,842
43,224
20,478
95,894
50,480
43,930
25,433
22,937
24,775
15,703
19,721
24,601
31,917
73,286
55,274
47,151
62,478
58,007
50,312
43,212
18,820
26,802
68,413
59,716
51,829
45,754
51,621
42,791
31,230
22,925
17,604
11,118
39,230
39,23011,11817,60422,92531,23042,79151,62145,75451,82959,71668,41326,80218,82043,21250,31258,00762,47847,15155,27473,28631,91724,60119,72115,70324,77522,93725,43343,93050,48095,89420,47843,22450,84270,238134,6986,41412,12516,55356,13418,07821,07728,19343,18814,77635,11934,06700
       Short-term Investments 
0
0
0
0
16,615
16,515
26,152
28,489
26,349
33,331
64,815
60,041
53,817
34,641
85,381
90,830
83,438
89,610
51,759
80,515
70,458
73,669
63,622
50,961
51,500
38,577
29,027
14,433
4,385
0
0
0
0
0
0
0
439
0
0
0
0
0
0
0
0
0
0
0
0000000000043900000004,38514,43329,02738,57751,50050,96163,62273,66970,45880,51551,75989,61083,43890,83085,38134,64153,81760,04164,81533,33126,34928,48926,15216,51516,6150000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,333
2,123
1,315
1,276
1,536
210
244
260
300
342
0
15,000
15,000
15,000
15,200
450
450
0
0
0
00045045015,20015,00015,00015,00003423002602442101,5361,2761,3152,1232,3330000000000000000000000000000
       Other Current Assets 
0
0
209
460
0
481
917
841
650
605
1,247
1,448
1,647
1,995
3,543
3,650
3,199
2,651
2,458
2,459
2,056
2,048
2,535
1,871
1,578
835
547
2,636
3,418
7,115
5,186
7,378
5,081
3,550
2,633
59
1,853
686
701
553
691
778
935
263
1,298
931
232
1,133
1,1332329311,2982639357786915537016861,853592,6333,5505,0817,3785,1867,1153,4182,6365478351,5781,8712,5352,0482,0562,4592,4582,6513,1993,6503,5431,9951,6471,4481,247605650841917481046020900
   > Long-term Assets 
0
0
709
747
849
983
978
818
2,468
2,693
3,214
3,885
3,694
4,443
5,292
7,485
8,752
9,321
8,611
8,944
6,099
5,169
4,791
4,418
4,072
3,896
1,358
248
652
3,812
4,827
3,838
3,421
3,060
2,749
3,038
2,313
5,003
4,585
4,275
4,243
3,044
2,914
13,139
12,656
12,207
11,696
11,240
11,24011,69612,20712,65613,1392,9143,0444,2434,2754,5855,0032,3133,0382,7493,0603,4213,8384,8273,8126522481,3583,8964,0724,4184,7915,1696,0998,9448,6119,3218,7527,4855,2924,4433,6943,8853,2142,6932,46881897898384974770900
       Property Plant Equipment 
0
0
434
654
756
895
890
730
880
1,202
1,909
3,103
3,367
4,159
4,208
6,717
8,313
8,667
8,149
8,047
5,572
4,707
3,956
3,606
3,113
2,935
403
108
797
2,349
3,568
3,331
2,866
2,616
2,360
2,987
2,014
4,891
4,473
4,164
3,763
2,564
2,231
12,710
12,227
11,809
11,303
10,792
10,79211,30311,80912,22712,7102,2312,5643,7634,1644,4734,8912,0142,9872,3602,6162,8663,3313,5682,3497971084032,9353,1133,6063,9564,7075,5728,0478,1498,6678,3136,7174,2084,1593,3673,1031,9091,20288073089089575665443400
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,508
0
112
112
111
480
480
683
0
0
398
0
0
003980068348048011111211202,50800000000000000000000000000000000000
> Total Liabilities 
0
0
1,810
1,914
2,093
2,105
1,827
2,221
5,844
6,361
7,132
8,874
10,247
6,683
7,747
10,221
11,763
13,216
12,165
12,521
14,325
11,597
12,744
9,737
8,555
5,696
5,323
4,323
10,952
13,299
13,650
15,099
13,406
12,188
9,024
91,656
6,079
27,383
23,606
37,121
37,596
36,419
36,398
27,978
26,364
25,730
25,177
24,835
24,83525,17725,73026,36427,97836,39836,41937,59637,12123,60627,3836,07991,6569,02412,18813,40615,09913,65013,29910,9524,3235,3235,6968,5559,73712,74411,59714,32512,52112,16513,21611,76310,2217,7476,68310,2478,8747,1326,3615,8442,2211,8272,1052,0931,9141,81000
   > Total Current Liabilities 
0
0
1,810
1,914
2,086
2,094
1,812
2,156
5,774
6,287
7,054
8,803
10,174
6,609
7,598
9,863
11,243
11,807
10,740
11,266
13,209
10,591
11,819
8,903
7,804
5,032
4,747
3,881
9,817
10,929
10,513
12,520
11,211
10,086
7,121
3,222
4,597
9,794
6,203
20,026
20,815
22,423
24,059
7,277
7,511
8,638
7,422
9,411
9,4117,4228,6387,5117,27724,05922,42320,81520,0266,2039,7944,5973,2227,12110,08611,21112,52010,51310,9299,8173,8814,7475,0327,8048,90311,81910,59113,20911,26610,74011,80711,2439,8637,5986,60910,1748,8037,0546,2875,7742,1561,8122,0942,0861,9141,81000
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
189
199
197
208
258
207
222
712
235
1,484
1,411
1,442
1,473
3,050
4,371
1,413
2,806
4,388
3,251
5,237
5,2373,2514,3882,8061,4134,3713,0501,4731,4421,4111,4842357122222072582081971991890000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,000
3,500
0
1,481
2,974
2,134
4,285
4,2852,1342,9741,48103,5002,00000000000000000000000000000000000000000000
       Accounts payable 
0
0
605
1,069
0
948
216
791
1,654
1,943
1,408
2,983
2,520
2,493
2,987
4,156
3,352
4,218
2,466
2,770
2,183
2,384
3,275
2,691
2,242
1,024
757
604
1,998
3,091
2,691
1,495
2,773
1,340
1,733
1,071
811
6,695
2,380
991
684
1,448
925
1,108
1,157
868
1,139
845
8451,1398681,1571,1089251,4486849912,3806,6958111,0711,7331,3402,7731,4952,6913,0911,9986047571,0242,2422,6913,2752,3842,1832,7702,4664,2183,3524,1562,9872,4932,5202,9831,4081,9431,65479121694801,06960500
       Other Current Liabilities 
0
0
1,205
845
0
1,146
1,596
1,365
4,120
4,344
5,646
5,820
7,654
4,116
4,611
5,707
7,891
7,589
8,274
8,496
11,026
8,207
8,544
6,212
5,228
4,008
3,990
3,277
7,630
7,639
7,625
10,817
8,180
8,539
5,166
6,262
3,551
1,615
2,412
19,035
18,658
17,925
18,763
4,756
3,548
3,382
3,032
3,329
3,3293,0323,3823,5484,75618,76317,92518,65819,0352,4121,6153,5516,2625,1668,5398,18010,8177,6257,6397,6303,2773,9904,0085,2286,2128,5448,20711,0268,4968,2747,5897,8915,7074,6114,1167,6545,8205,6464,3444,1201,3651,5961,14608451,20500
   > Long-term Liabilities 
0
0
41,192
0
7
11
15
65
70
74
78
71
73
74
149
358
520
1,409
1,425
1,255
1,116
1,006
925
834
751
664
576
442
1,135
2,370
3,137
2,579
2,195
2,102
1,903
88,434
1,482
17,589
17,403
17,095
16,781
13,996
12,339
20,701
18,853
17,092
17,755
15,424
15,42417,75517,09218,85320,70112,33913,99616,78117,09517,40317,5891,48288,4341,9032,1022,1952,5793,1372,3701,1354425766647518349251,0061,1161,2551,4251,4095203581497473717874706515117041,19200
> Total Stockholder Equity
0
0
33,175
34,412
0
59,062
54,413
49,004
41,701
86,402
78,697
68,625
55,325
169,094
156,707
142,586
126,850
108,844
146,557
129,877
108,218
94,722
81,141
72,288
64,298
57,333
50,210
44,911
70,951
52,966
43,074
58,547
53,830
44,276
39,146
-68,793
24,960
48,114
43,536
36,117
29,357
34,932
26,773
18,111
10,965
5,012
-1,190
26,768
26,768-1,1905,01210,96518,11126,77334,93229,35736,11743,53648,11424,960-68,79339,14644,27653,83058,54743,07452,96670,95144,91150,21057,33364,29872,28881,14194,722108,218129,877146,557108,844126,850142,586156,707169,09455,32568,62578,69786,40241,70149,00454,41359,062034,41233,17500
   Common Stock
0
0
3
14
0
18
17
17
18
23
24
24
24
27
27
27
27
27
36
36
36
36
36
36
36
36
36
36
13
13
13
18
19
19
19
1
19
7
7
7
7
10
10
11
11
13
14
22
221413111110107777191191919181313133636363636363636363627272727272424242318171718014300
   Retained Earnings Total Equity000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
-6,200
-36,326
-93
-141
-26
3
-688
-3
-8
-950
-1,138
-1,343
-1,556
-1,883
-2,420
-2,924
-3,454
-4,027
-3,620
-4,272
-3,917
-4,043
-3,700
-4,030
-1,860
-1,670
139
140
123
0
123
118
274
452
277
-75,497
-89
0
0
0
0
0
0
0
0
0
000000000-89-75,4972774522741181230123140139-1,670-1,860-4,030-3,700-4,043-3,917-4,272-3,620-4,027-3,454-2,924-2,420-1,883-1,556-1,343-1,138-950-8-3-6883-26-141-93-36,326-6,20000
   Capital Surplus 000000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
41,996
46,340
0
80,476
81,683
83,165
87,549
139,371
141,558
145,359
151,137
282,314
287,630
291,758
297,160
301,416
358,218
361,402
361,979
364,358
368,607
369,248
369,442
370,177
368,586
368,777
235,024
237,276
239,016
267,183
274,463
275,581
276,551
277,647
278,113
132,281
68,760
136,173
137,904
152,644
153,432
153,872
154,362
155,988
156,571
192,009
192,009156,571155,988154,362153,872153,432152,644137,904136,17368,760132,281278,113277,647276,551275,581274,463267,183239,016237,276235,024368,777368,586370,177369,442369,248368,607364,358361,979361,402358,218301,416297,160291,758287,630282,314151,137145,359141,558139,37187,54983,16581,68380,476046,34041,99600



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-381
Gross Profit-381-381
 
Operating Income (+$)
Gross Profit-381
Operating Expense-28,776
Operating Income-29,157-29,157
 
Operating Expense (+$)
Research Development17,498
Selling General Administrative11,659
Selling And Marketing Expenses381
Operating Expense28,77629,538
 
Net Interest Income (+$)
Interest Income1,100
Interest Expense-1,449
Other Finance Cost-1,155
Net Interest Income-1,504
 
Pretax Income (+$)
Operating Income-29,157
Net Interest Income-1,504
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-29,491-28,823
EBIT - interestExpense = -30,606
-29,491
-28,042
Interest Expense1,449
Earnings Before Interest and Taxes (EBIT)-29,157-28,042
Earnings Before Interest and Taxes (EBITDA)-28,776
 
After tax Income (+$)
Income Before Tax-29,491
Tax Provision-0
Net Income From Continuing Ops-31,106-29,491
Net Income-29,491
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses29,157
Total Other Income/Expenses Net-3341,504
 

Technical Analysis of Tempest Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Tempest Therapeutics Inc. The general trend of Tempest Therapeutics Inc is NEUTRAL with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Tempest Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (0.0%) Bearish trend (0.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Tempest Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 3.57 < 6 < 9.77.

The bearish price targets are: 3.03 > 2.88 > 2.7606.

Tweet this
Tempest Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Tempest Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 7/14.
The longshort score for the Moving Averages is 0/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Tempest Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Tempest Therapeutics Inc. The current macd is -0.1376827.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Tempest Therapeutics Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Tempest Therapeutics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Tempest Therapeutics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Tempest Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartTempest Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Tempest Therapeutics Inc. The current adx is 18.06.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Tempest Therapeutics Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Tempest Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Tempest Therapeutics Inc. The current sar is 5.34369587.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Tempest Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Tempest Therapeutics Inc. The current rsi is 39.25. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Tempest Therapeutics Inc Daily Relative Strength Index (RSI) ChartTempest Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Tempest Therapeutics Inc. The current phase is Oversold in neutral market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Tempest Therapeutics Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Tempest Therapeutics Inc Daily Stochastic Oscillator ChartTempest Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Tempest Therapeutics Inc. The current cci is -105.62904824.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Tempest Therapeutics Inc Daily Commodity Channel Index (CCI) ChartTempest Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Tempest Therapeutics Inc. The current cmo is -31.86822151.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Tempest Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartTempest Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Tempest Therapeutics Inc. The current willr is -100.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Tempest Therapeutics Inc Daily Williams %R ChartTempest Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Tempest Therapeutics Inc.

Tempest Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Tempest Therapeutics Inc. The current atr is 0.4009043.

Tempest Therapeutics Inc Daily Average True Range (ATR) ChartTempest Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Tempest Therapeutics Inc. The current obv is 400,534,767.

Tempest Therapeutics Inc Daily On-Balance Volume (OBV) ChartTempest Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Tempest Therapeutics Inc. The current mfi is 75.85.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Tempest Therapeutics Inc Daily Money Flow Index (MFI) ChartTempest Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Tempest Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-11-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-30MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-12CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-14CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-20CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-27MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-03STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-05CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-16CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-17CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-25WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-31STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-14CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-27CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-04BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-01WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-02RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-04RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-17STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Tempest Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Tempest Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.251
Ma 20Greater thanMa 503.907
Ma 50Greater thanMa 1003.810
Ma 100Greater thanMa 2003.874
OpenGreater thanClose3.300
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Tempest Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Tempest Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Tempest Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Tempest Therapeutics Inc

I send you an email if I find something interesting about Tempest Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Tempest Therapeutics Inc.

Receive notifications about Tempest Therapeutics Inc in your mailbox!